Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

Sponsor
Lecube, Albert, M.D.
Study ID
NCT02889510
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    7-week subcutaneous liraglutide once daily
  • placebo — DRUG
    7-week subcutaneous placebo once daily

Study Details

Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in significant amounts in the lung, it could be hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced pulmonary function

Key Dates

Start date
Oct 4, 2016
Status verified
Jan 2021
Primary completion
Nov 18, 2019
Completion
Dec 16, 2019

Study Design

Enrollment
76 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Other: liraglutide
    7-week subcutaneous liraglutide treatment once daily
  • Other: placebo
    7-week subcutaneous placebo treatment once daily.

Primary Outcome Measure

Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: 7 weeks ]

Related Studies